IL158550A0 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same - Google Patents

Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Info

Publication number
IL158550A0
IL158550A0 IL15855002A IL15855002A IL158550A0 IL 158550 A0 IL158550 A0 IL 158550A0 IL 15855002 A IL15855002 A IL 15855002A IL 15855002 A IL15855002 A IL 15855002A IL 158550 A0 IL158550 A0 IL 158550A0
Authority
IL
Israel
Prior art keywords
inhibitors
identifying
methods
same
inhibitory factor
Prior art date
Application number
IL15855002A
Other languages
English (en)
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of IL158550A0 publication Critical patent/IL158550A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL15855002A 2001-05-24 2002-05-24 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same IL158550A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29364201P 2001-05-24 2001-05-24
PCT/US2002/016963 WO2002094203A2 (en) 2001-05-24 2002-05-24 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Publications (1)

Publication Number Publication Date
IL158550A0 true IL158550A0 (en) 2004-05-12

Family

ID=23129922

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15855002A IL158550A0 (en) 2001-05-24 2002-05-24 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Country Status (24)

Country Link
US (14) US7105519B2 (hu)
EP (1) EP1389110B1 (hu)
JP (1) JP4346312B2 (hu)
KR (1) KR100896973B1 (hu)
CN (1) CN1523989A (hu)
AR (1) AR036032A1 (hu)
AT (1) ATE461920T1 (hu)
AU (2) AU2002303906B2 (hu)
BR (1) BR0209948A (hu)
CA (1) CA2447103A1 (hu)
CZ (1) CZ20033503A3 (hu)
DE (1) DE60235750D1 (hu)
ES (1) ES2342877T3 (hu)
HU (1) HUP0500101A3 (hu)
IL (1) IL158550A0 (hu)
MX (1) MXJL03000038A (hu)
MY (1) MY140679A (hu)
NZ (1) NZ529244A (hu)
PL (1) PL367127A1 (hu)
PT (1) PT1389110E (hu)
RU (1) RU2327695C2 (hu)
UY (1) UY27304A1 (hu)
WO (1) WO2002094203A2 (hu)
ZA (1) ZA200309738B (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352228T3 (es) 2001-03-29 2011-02-16 Cytokine Pharmasciences, Inc. Procedimiento y composiciones para usar el polipéptido de cadena invariante de mhc de clase ii como receptor para el factor inhibidor de la migración de macrófagos.
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
AU2003235122A1 (en) 2002-04-26 2003-11-10 Takeda Chemical Industries, Ltd. Cell death inhibitor
RU2005102004A (ru) 2002-06-27 2005-10-20 Шеринг Акциенгезельшафт (De) Замещенные хинолины как антагонисты рецептора ccr5
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7364869B2 (en) * 2003-07-29 2008-04-29 The J. David Gladstone Institutes Method of detecting antigen-specific T lymphocytes
EP1656376A1 (en) * 2003-08-22 2006-05-17 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
AU2011265309B2 (en) * 2003-11-21 2014-06-05 Array Biopharma, Inc. AKT protein kinase inhibitors
CN1882347A (zh) 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
JP5198848B2 (ja) * 2004-03-29 2013-05-15 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ マクロファージ遊走阻止因子阻害剤を用いる、１型糖尿病処置
DE102004029573A1 (de) * 2004-06-18 2005-12-29 Gambro Lundia Ab MIF-Adsorbent
AU2004323369A1 (en) * 2004-09-17 2006-03-23 Siang Beng Chng System and method for batch conversion of RFID tag to RFID label
EP1861407A1 (en) * 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
US7915285B2 (en) * 2005-09-26 2011-03-29 The Regents Of The University Of Colorado Method for treating drug and behavioral addictions
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
CA2647163C (en) 2006-03-24 2016-06-21 The Feinstein Institute For Medical Research Modified macrophage migration inhibitory factor inhibitors
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
US20070281924A1 (en) * 2006-05-31 2007-12-06 Gaeta Federico C MIF inhibitors for treating neuropathic pain and associated syndromes
US7845914B2 (en) * 2007-02-15 2010-12-07 Deere & Company Self-priming fast fill sprayer pump system
US9272034B2 (en) * 2007-10-04 2016-03-01 The Regents Of The University Of California Treatment of conditions related to shock
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
GB2497476B (en) 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
CN103237558A (zh) 2010-10-02 2013-08-07 加利福尼亚大学董事会 最小化肠功能障碍
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
CA2911041C (en) 2012-05-01 2020-12-15 Shelley Romayne BOYD Methods for treating and diagnosing blinding eye diseases
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
BR112018000925A2 (pt) * 2015-07-17 2018-09-11 Toyama Chemical Co., Ltd composto heterocíclico contendo nitrogênio
CN111518077B (zh) * 2018-01-17 2021-02-26 杭州阿诺生物医药科技有限公司 一种新型抗肿瘤ido抑制剂的制备方法
AU2019252676A1 (en) 2018-04-11 2020-11-26 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
KR20200144109A (ko) 2018-04-13 2020-12-28 캔써 리서치 테크놀로지 리미티드 Bcl6 저해제
SG11202012972YA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Substituted naphthyridinone compounds useful as t cell activators
SI3814347T1 (sl) 2018-06-27 2023-07-31 Bristol-Myers Squibb Company Naftiridinonske spojine uporabne kot T celični aktivatorji
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN113121435B (zh) * 2021-04-20 2022-08-30 辽宁大学 一种2,4-二氯喹啉类化合物的合成方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US4299814A (en) 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
US4284768A (en) * 1980-07-02 1981-08-18 American Home Products Corporation 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
DK79985A (da) 1984-02-22 1985-08-23 Wellcome Found Kloning af dna for protozoelle antigener og dets anvendelse
US5801200A (en) 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5700447A (en) 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5733524A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
AU592753B2 (en) 1984-05-24 1990-01-25 Ciba-Geigy Ag Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications
JPH0672158B2 (ja) 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4708937A (en) 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8602626D0 (en) 1986-02-04 1986-03-12 Ciba Geigy Ag Neurite-promoting factor
EP0263072B1 (en) 1986-10-03 1994-03-23 Ciba-Geigy Ag Novel lymphokine related peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463037A1 (en) 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor
FI82144C (fi) 1989-03-22 1991-01-10 Wallac Oy Foerfarande foer samtidig bestaemning av flera ligander.
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5328990A (en) 1991-04-26 1994-07-12 The United States Of America As Represented By The Department Of Health And Human Services Isolation of macrophage migration inhibition factor from ocular lens
CA2054602C (en) 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US6080407A (en) 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
AU692159B2 (en) 1993-05-17 1998-06-04 Cytokine Pharmasciences, Inc. Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US5650295A (en) 1995-06-02 1997-07-22 Human Genone Sciences, Inc. Macrophage migration inhibitory factor-3
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
US5955203A (en) 1994-10-05 1999-09-21 Simpson Timber Company Resin-coated overlays for solid substrates
WO1996015242A2 (en) 1994-11-16 1996-05-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
DE19601697A1 (de) 1996-01-18 1997-07-24 Wacker Chemie Gmbh Redispergierbare Tackifierpulver
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
CA2250067A1 (en) 1996-04-18 1997-10-23 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US5883224A (en) 1996-04-19 1999-03-16 Cytokine Sciences, Inc. Characterization of transfer factors and methods of use
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
WO2000007007A1 (en) 1998-07-28 2000-02-10 Biometric Imaging, Inc. Device and method for cell motility assay
EP1102848B1 (en) 1998-08-07 2010-10-13 Immunex Corporation Molecules designated ldcam
US6214343B1 (en) 1999-05-24 2001-04-10 Ophidian Pharmaceuticals, Inc. Prevention and treatment of necrotizing enterocolitis
JP2003513065A (ja) * 1999-10-29 2003-04-08 ザ・ピコワー・インスティチュート・フォー・メディカル・リサーチ Ｍｉｆアンタゴニスト活性を有する化合物
EP1465660A4 (en) 2001-01-12 2005-09-21 Cytokine Pharmasciences Inc METHOD AND COMPOSITIONS FOR MODULATING THE REGULATION OF THE CYTOTOXIC LYMPHOCYTE RESPONSE BY MACROPHAGE MIGRATION HEMM FACTOR
ES2352228T3 (es) 2001-03-29 2011-02-16 Cytokine Pharmasciences, Inc. Procedimiento y composiciones para usar el polipéptido de cadena invariante de mhc de clase ii como receptor para el factor inhibidor de la migración de macrófagos.
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
EP1424336A4 (en) 2001-09-03 2004-11-10 Takeda Chemical Industries Ltd 1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE
FR2829491B1 (fr) 2001-09-12 2005-09-30 Diverchim Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase
WO2003065979A2 (en) 2001-12-05 2003-08-14 North Shore-Long Island Jewish Research Institute Methods of diagnosis, monitoring and treatment of fertility
US20040019921A1 (en) 2001-12-19 2004-01-29 Fingerle-Rowson Gunter R. Non-human mammal with disrupted or modified MIF gene, and uses thereof
AU2003235122A1 (en) 2002-04-26 2003-11-10 Takeda Chemical Industries, Ltd. Cell death inhibitor
JP4828823B2 (ja) 2002-06-07 2011-11-30 コーティカル・ピーティーワイ・リミテッド 治療用分子および方法−１
AU2003229142A1 (en) 2002-06-07 2003-12-22 Cortical Pty Ltd Naphthalene derivatives which inhibit the cytokine or biological activity of macrophage inhibitory factor (MIF)
BR0314577A (pt) 2002-09-18 2005-08-09 Pfizer Prod Inc Derivados de triazol como inibidores do fator de crescimento de transformação (tgf)
AU2003289176A1 (en) 2002-12-05 2004-07-29 Takeda Pharmaceutical Company Limited 1,3-benzothiazinone derivatives, process for producing the same and use thereof
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7361474B2 (en) 2003-02-24 2008-04-22 United States Of America As Represented By The Department Of Veterans Affairs Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
EP1656376A1 (en) * 2003-08-22 2006-05-17 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
EP1861407A1 (en) * 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors

Also Published As

Publication number Publication date
US20060194793A1 (en) 2006-08-31
ZA200309738B (en) 2004-10-04
US20060194818A1 (en) 2006-08-31
NZ529244A (en) 2006-04-28
PL367127A1 (en) 2005-02-21
ES2342877T3 (es) 2010-07-16
US7157469B2 (en) 2007-01-02
AU2002303906B2 (en) 2007-06-28
EP1389110A4 (en) 2004-10-20
US7192961B2 (en) 2007-03-20
HUP0500101A2 (hu) 2005-05-30
US7238809B2 (en) 2007-07-03
US7732146B2 (en) 2010-06-08
PT1389110E (pt) 2010-07-01
KR20040041095A (ko) 2004-05-13
WO2002094203A3 (en) 2003-04-10
JP4346312B2 (ja) 2009-10-21
US20030195194A1 (en) 2003-10-16
US7514225B2 (en) 2009-04-07
CA2447103A1 (en) 2002-11-28
RU2003132534A (ru) 2005-04-20
US7084141B2 (en) 2006-08-01
WO2002094203A2 (en) 2002-11-28
MXJL03000038A (es) 2004-12-03
US7105519B2 (en) 2006-09-12
CN1523989A (zh) 2004-08-25
EP1389110A2 (en) 2004-02-18
DE60235750D1 (de) 2010-05-06
RU2327695C2 (ru) 2008-06-27
HUP0500101A3 (en) 2009-09-28
US7235565B2 (en) 2007-06-26
US7432374B2 (en) 2008-10-07
BR0209948A (pt) 2004-12-21
US20060194792A1 (en) 2006-08-31
UY27304A1 (es) 2002-12-31
AU2007201493A1 (en) 2007-04-26
US7230106B2 (en) 2007-06-12
CZ20033503A3 (cs) 2004-08-18
US7129236B2 (en) 2006-10-31
KR100896973B1 (ko) 2009-05-14
US20070021440A1 (en) 2007-01-25
US20060199825A1 (en) 2006-09-07
US20050282236A1 (en) 2005-12-22
US7202248B2 (en) 2007-04-10
US20070232613A1 (en) 2007-10-04
ATE461920T1 (de) 2010-04-15
US20060235023A1 (en) 2006-10-19
EP1389110B1 (en) 2010-03-24
US20050287617A1 (en) 2005-12-29
US20060199827A1 (en) 2006-09-07
US20060094727A1 (en) 2006-05-04
MY140679A (en) 2010-01-15
AR036032A1 (es) 2004-08-04
JP2005500266A (ja) 2005-01-06
US20060205734A1 (en) 2006-09-14
US7435737B2 (en) 2008-10-14
US20070197547A1 (en) 2007-08-23
US7192955B2 (en) 2007-03-20

Similar Documents

Publication Publication Date Title
HUP0500101A3 (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
ZA200507170B (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AU2003302248A8 (en) Method and system for determining characteristics of substrates employing fluid geometries
EP1507756A4 (en) CCR9 INHIBITORS AND USE THEREOF
AU2003303128A1 (en) Inhibitors and methods of use thereof
EP1377587A4 (en) PROTEIN INHIBITORS PHOSPHATE
ZA200408459B (en) System and method for use of multiple applications
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2003256945A8 (en) Vapor-liquid contact trays and method employing same
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
EP1448218A4 (en) BETA SECRETASE INHIBITORS AND METHODS OF USE
AU2003247659A8 (en) Vapor-liquid contact tray and method employing same
EP1539248A4 (en) INHIBITOR OF S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF SUPPRESSING CANCER USING THIS HEMMER
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
IL160620A0 (en) Combinations comprising cox-2 inhibitors and aspirin
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
GB0124700D0 (en) Method for the secure distribution and use of media electronic media
EP1468265A4 (en) SYSTEMS AND METHOD FOR PROTEIN PHOSPHORYLATION ANALYSIS
AU2003210741A1 (en) Ptpase inhibitors and methods of using the same
AU2003267790A8 (en) Lipase inhibitors and uses thereof
GB0109278D0 (en) Enzyme inhibitors
AU2003269954A8 (en) Measurement systems and methods
IL165870A0 (en) Use of chymase inhibitors for the prevention and/or
AU2002328342A1 (en) Kinase inhibitors and the use thereof